All news

Cantor Fitzgerald cuts Bristol Myers Squibb price target

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Cantor Fitzgerald lowered its price target on Bristol Myers Squibb (NYSE:BMY) to $53 from $59 while keeping a neutral rating, implying roughly 11.2% downside. The biopharmaceutical company still holds a Moderate Buy consensus, with an average price target of $66.72. Bristol Myers Squibb recently reported quarterly earnings that beat analyst expectations, posting $2.04 in earnings per share on

Read original source

BMY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.